Automated planar patch clamp systems are widely used in drug evaluation studies because of their ability to provide accurate, reliable, and reproducible data in a high-throughput manner. Typically, CHO and HEK tumorigenic cell lines overexpressing single ion channels are used since they can be harvested as high-density, homogenous, single-cell suspensions. While human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are physiologically more relevant, these cells are fragile, have complex culture requirements, are inherently heterogeneous, and are expensive to produce, which has restricted their use on automated patch clamp (APC) devices. Here, we used high efficiency differentiation protocols to produce cardiomyocytes from six different hPSC lines for analysis on the Patchliner (Nanion Technologies GmbH) APC platform. We developed a two-step cell preparation protocol that yielded cell catch rates and whole-cell breakthroughs of ∼80%, with ∼40% of these cells allowing electrical activity to be recorded. The protocol permitted formation of long-lasting (>15 min), high quality seals (>2 GΩ) in both voltage- and current-clamp modes. This enabled density of sodium, calcium, and potassium currents to be evaluated, along with dose–response curves to their respective channel inhibitors, tetrodotoxin, nifedipine, and E-4031. Thus, we show the feasibility of using the Patchliner platform for automated evaluation of the electrophysiology and pharmacology of hPSC-CMs, which will enable considerable increase in throughput for reliable and efficient drug evaluation.
Get full access to this article
View all access options for this article.
References
1.
HutchinsonL and KirkR. (2011). High drug attrition rates—where are we going wrong?. Nat Rev Clin Oncol, 8:189–190.
2.
NgR. (2015). An overview of the drug discovery to approval process. In: Drugs: From Discovery to Approval. John Wiley and Sons, Inc., Hoboken, NJ, pp 2–6.
3.
QureshiZP, Seoane-VazquezE, Rodriguez-MonguioR, StevensonKB and SzeinbachSL. (2011). Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf, 20:772–777.
4.
GwathmeyJK, TsaiounK and HajjarRJ. (2009). Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin Drug Metab Toxicol, 5:647–660.
5.
SchachterAD and RamoniMF. (2007). Clinical forecasting in drug development. Nat Rev Drug Discov, 6:107–108.
6.
RajamohanD, MatsaE, KalraS, CrutchleyJ, PatelA, GeorgeV and DenningC. (2013). Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays, 35:281–298.
7.
MeyerT, LeisgenC, GonserB and GuntherE. (2004). QT-Screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev Technol, 2:507–514.
8.
YanGX, ShimizuW and AntzelevitchC. (1998). Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation, 98:1921–1927.
9.
VarroA, BalatiB, IostN, TakacsJ, ViragL, LathropDA, CsabaL, TalosiL and PappJG. (2000). The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol, 523Pt 1:67–81.
10.
DickE, RajamohanD, RonksleyJ and DenningC. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans, 38:1037–1045.
11.
WehrensXHT, KirchhoffS and DoevendansPA. (2000). Mouse electrocardiography: an interval of thirty years. Cardiovasc Res, 45:231–237.
12.
ZhangM, SchulteJS, HeinickA, PicciniI, RaoJ, QuarantaR, ZeuschnerD, MalanD, KimK-P, RoepkeA, et al. (2015). Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation. Stem Cells, 33:1456–1469.
13.
DenningC, BorgdorffV, CrutchleyJ, FirthKSA, GeorgeV, KalraS, KondrashovA, HoangMD, MosqueiraD, et al. (2015). Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta, Pt 2: S0167-4889.
14.
BurridgePW, KellerG, GoldJD and WuJC. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell, 10:16–28.
15.
BraamSR, TertoolenL, van de StolpeA, MeyerT, PassierR and MummeryCL. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res, 4:107–116.
16.
HarrisK, AylottM, CuiY, LouttitJB, McMahonNC and SridharA. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell–derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci, 134:412–426.
MorettiA, BellinM, WellingA, JungCB, LamJT, Bott-FlügelL, DornT, GoedelA, HohnkeC and HofmannF. (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med, 363:1397–1409.
19.
ItzhakiI, MaizelsL, HuberI, Zwi-DantsisL, CaspiO, WintersternA, FeldmanO, GepsteinA, ArbelG and HammermanH. (2011). Modelling the long QT syndrome with induced pluripotent stem cells. Nature, 471:225–229.
20.
MatsaE, RajamohanD, DickE, YoungL, MellorI, StaniforthA and DenningC. (2011). Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J, 32:952–962.
21.
MatsaE, DixonJE, MedwayC, GeorgiouO, PatelMJ, MorganK, KempPJ, StaniforthA, MellorI and DenningC. (2014). Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J, 35:1078–1087.
22.
LahtiAL, KujalaVJ, ChapmanH, KoivistoAP, Pekkanen-MattilaM, KerkelaE, HyttinenJ, KontulaK, SwanH, et al. (2011). Human disease model for long QT syndrome type 2 using iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech, 5:220–230.
23.
MaD, WeiH, ZhaoY, LuJ, LiG, SahibNBE, TanTH, WongKY, ShimW, et al. (2013). Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol, 168:5277–5286.
24.
YazawaM, HsuehB, JiaX, PascaAM, BernsteinJA, HallmayerJ and DolmetschRE. (2011). Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature, 471:230–234.
25.
FatimaA, XuG, ShaoK, PapadopoulosS, LehmannM, Arnaiz-CotJJ, RosaAO, NguemoF, MatzkiesM, et al. (2011). In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem, 28:579–592.
26.
JungCB, MorettiA, MederosM, SchnitzlerY, IopL, StorchU, BellinM, DornT, RuppenthalS, et al. (2012). Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med, 4:180–191.
27.
TerrenoireC, WangK, Chan TungKW, ChungWK, PassRH, LuJT, JeanJ-C, OmariA, SampsonKJ, et al. (2013). Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol, 141:61–72.
28.
SagerPT, GintantG, TurnerJR, PettitS and StockbridgeN. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J, 167:292–300.
29.
FarreC and FertigN. (2012). HTS techniques for patch clamp-based ion channel screening—advances and economy. Expert Opin Drug Discov, 7:515–524.
30.
BrueggemannA, FarreC, HaarmannC, HaythornthwaiteA, KreirM, StoelzleS, GeorgeM and FertigN. (2008). Planar patch clamp: advances in electrophysiology. Methods Mol Biol, 491:165–176.
31.
MaJ, GuoL, FieneSJ, AnsonBD, ThomsonJA, KampTJ, KolajaKL, SwansonBJ and JanuaryCT. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol, 301:H2006–H2017.
32.
StoelzleS, ObergrussbergerA, BrueggemannA, HaarmannC, GeorgeM, KettenhofenR and FertigN. (2011). State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening. Front Pharmacol, 2:76.
33.
DickE, MatsaE, YoungLE, DarlingD and DenningC. (2011). Faster generation of hiPSCs by coupling high-titer lentivirus and column-based positive selection. Nat Protoc, 6:701–714.
34.
BurridgePW, ThompsonS, MillrodMA, WeinbergS, YuanX, PetersA, MahairakiV, KoliatsosVE, TungL and ZambidisET. (2011). A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One, 6:e18293.
35.
MaheraliN and HochedlingerK. (2008). Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell, 3:595–605.
36.
HuangH-L, HsingH-W, LaiT-C, ChenY-W, LeeT-R, ChanH-T, LyuP-C, WuC-L, LuY-C, et al. (2010). Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci, 17:36.
37.
BeckerN, StoelzleS, GopelS, GuinotD, MummP, HaarmannC, MalanD, BohlenH, KossolovE, et al. (2013). Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods, 68:82–87.
38.
SakmannB and NeherE. (1984). Patch clamp technique for studying ionic channels in excitable membranes. Annu Rev Physiol, 46:455–472.
39.
HartmanME, DaiD-F and LaflammeMA. (2016). Human pluripotent stem cells: prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. Adv Drug Deliv Rev, 96:3–17.
40.
SchroderRL, ChristensenM, AnsonB and SunesenM. (2012). Exploring stem cell-derived cardiomyocytes with automated patch clamp techniques. Biophys J, 102:544A.
41.
HaythornthwaiteA, StoelzleS, HaslerA, KissA, MosbacherJ, GeorgeM, BrueggemannA and FertigN. (2012). Characterizing human ion channels in induced pluripotent stem cell-derived neurons. J Biomol Screen, 17:1264–1272.
42.
YajuanX, XinL and ZhiyuanL. (2012). A comparison of the performance and application differences between manual and automated patch-clamp techniques. Curr Chem Genomics, 6:87–92.
43.
KirkpatrickCJ, MelznerI and GöllerT. (1985). Comparative effects of trypsin, collagenase and mechanical harvesting on cell membrane lipids studied in monolayer-cultured endothelial cells and a green monkey kidney cell line. Biochim Biophys Acta, 846:120–126.
44.
SatinJ, KehatI, CaspiO, HuberI, ArbelG, ItzhakiI, MagyarJ, SchroderEA, PerlmanI and GepsteinL. (2004). Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol, 559:479–496.
45.
SakakibaraY, FurukawaT, SingerDH, JiaHJ, BackerCL, ArentzenCE and WasserstromJA. (1993). Sodium current in isolated human ventricular myocytes. Am J Physiol, 265:H1301–H1309.
46.
PelzmannB, SchafferP, BernhartE, LangP, MachlerH, RiglerB and KoidlB. (1998). L-type calcium current in human ventricular myocytes at a physiological temperature from children with tetralogy of Fallot. Cardiovasc Res, 38:424–432.
47.
TipparajuSM, KumarR, WangYG, JoynerRW and WagnerMB. (2004). Developmental differences in L-type calcium current of human atrial myocytes. Am J Physiol Heart Circ Physiol, 286:H1963–H1969.
48.
JostN, AcsaiK, HorvathB, BanyaszT, BaczkoI, BitayM, BogatsG and NanasiPP. (2009). Contribution of IKr and IK1 to ventricular repolarization in canine and human myocytes: is there any influence of action potential duration?. Basic Res Cardiol, 104:33–41.
49.
ShengX, ReppelM, NguemoF, MohammadFI, KuzmenkinA, HeschelerJ and PfannkucheK. (2012). Human pluripotent stem cell-derived cardiomyocytes: response to TTX and Lidocain reveals strong cell to cell variability. PLoS One, 7:e45963.
50.
PrioriSG, NapolitanoC, Di PasqualeE and CondorelliG. (2013). Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest, 123:84–91.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
